#1 Clinical Trials Search in Europe

Temozolomide

Temozolomide, also known by brand names like Temodal and Temodar, is a chemotherapy drug that has become a cornerstone in the treatment of various brain cancers, particularly glioblastoma. This article explores recent clinical trials investigating new ways to use temozolomide, either alone or in combination with other treatments, to improve outcomes for patients with brain tumors. These trials aim to enhance the effectiveness of temozolomide while managing its side effects and exploring its potential in different treatment regimens.

Table of Contents

What is Temozolomide?

Temozolomide is an oral chemotherapy drug used to treat various types of cancers, particularly those affecting the brain and central nervous system. It is also known by its brand names Temodar, Temodal, and ACH-TEMOZOLOMIDE[7]. Temozolomide belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells, preventing them from dividing and growing[2].

How Does Temozolomide Work?

Temozolomide works by adding small chemical groups called methyl groups to the DNA of cancer cells. This process is known as DNA methylation. When these methyl groups are added to specific parts of the DNA, it can cause damage that the cancer cells cannot repair. This damage leads to the death of cancer cells or prevents them from dividing and spreading[2].

The effectiveness of Temozolomide can be influenced by a protein called O6-methylguanine-DNA methyltransferase (MGMT). This protein can repair some of the DNA damage caused by Temozolomide. In some cancers, the gene that produces MGMT is “silenced” or turned off, which can make the cancer more sensitive to Temozolomide treatment[2].

Conditions Treated with Temozolomide

Temozolomide is used to treat several types of cancers, including:

  • Glioblastoma: A type of aggressive brain cancer[1]
  • Anaplastic gliomas: Grade III brain tumors[6]
  • Metastatic melanoma: Advanced skin cancer that has spread to other parts of the body[5]
  • Small cell lung cancer: A type of lung cancer[3]
  • Non-small cell lung cancer: Another type of lung cancer[4]

It’s important to note that Temozolomide is often used in combination with other treatments, such as surgery and radiation therapy, to provide the best possible outcomes for patients.

How is Temozolomide Administered?

Temozolomide is typically taken orally in the form of capsules. The dosage and schedule can vary depending on the specific condition being treated and the individual patient. Some common administration schedules include:

  • Daily for 5 days, followed by a 23-day break (28-day cycle)[3]
  • Daily for 21 days, followed by a 7-day break (28-day cycle)[3]
  • “Dose-dense” schedules, such as 7 days on, 7 days off[8]

Your healthcare provider will determine the best dosage and schedule for your specific situation. It’s crucial to take Temozolomide exactly as prescribed and to inform your doctor of any side effects you experience.

Side Effects of Temozolomide

Like all chemotherapy drugs, Temozolomide can cause side effects. Some common side effects include:

  • Nausea and vomiting
  • Fatigue
  • Loss of appetite
  • Headache
  • Constipation

More serious side effects can include:

  • Low blood cell counts: This can increase the risk of infection, anemia, and bleeding[7]
  • Liver problems
  • Allergic reactions

Your healthcare team will monitor you closely for these side effects and may adjust your treatment if necessary. It’s important to report any side effects you experience to your doctor promptly.

Ongoing Research and Clinical Trials

Researchers are continually working to improve the effectiveness of Temozolomide and explore its potential in treating various cancers. Some areas of ongoing research include:

  • Combination therapies: Studies are investigating the use of Temozolomide in combination with other drugs, such as PARP inhibitors like Niraparib, to potentially enhance its effectiveness[8].
  • Alternative dosing schedules: Researchers are exploring different ways of administering Temozolomide to improve its efficacy and reduce side effects[8].
  • Biomarkers for treatment response: Studies are looking at genetic markers, such as MGMT methylation status, to better predict which patients will respond best to Temozolomide treatment[2].
  • Use in pediatric cancers: Clinical trials are investigating the safety and effectiveness of Temozolomide in children with various types of solid tumors[7].

These ongoing studies aim to improve outcomes for patients and expand the use of Temozolomide in cancer treatment. If you’re interested in participating in a clinical trial, discuss this option with your healthcare provider to determine if it might be appropriate for your situation.

Aspect Details
Main Focus Investigating temozolomide in various brain cancer treatments
Cancer Types Glioblastoma, anaplastic gliomas, malignant gliomas
Combination Therapies With radiation, bevacizumab, irinotecan, carboxyamidotriazole orotate
Administration Methods Oral, various schedules (e.g., daily for 5 days every 28 days, 7 days on/7 days off)
Key Objectives Improve efficacy, reduce side effects, optimize dosing, explore new combinations
Outcome Measures Progression-free survival, overall survival, tumor response, safety profile
Novel Approaches Dietary interventions, bioequivalence studies, exploration of genetic markers

FAQ

  • What is temozolomide and how does it work? Temozolomide is a chemotherapy drug used to treat brain tumors. It works by damaging the DNA of cancer cells, which prevents them from dividing and growing. Temozolomide is taken orally and can cross the blood-brain barrier, making it effective for treating brain cancers.
  • What types of brain cancers are being treated with temozolomide in these clinical trials? The clinical trials are exploring the use of temozolomide in various brain cancers, including glioblastoma, anaplastic gliomas, and other malignant gliomas. Some trials are also investigating its use in newly diagnosed cases as well as recurrent tumors.
  • Are there any new combination therapies being tested with temozolomide? Yes, several trials are testing temozolomide in combination with other treatments. For example, some studies are combining it with drugs like bevacizumab (Avastin) and irinotecan, while others are exploring its use alongside radiation therapy or new drugs like carboxyamidotriazole orotate (CTO).
  • How is temozolomide typically administered in these trials? Temozolomide is usually given orally in cycles. The dosage and schedule can vary, but common regimens include daily doses for 5 days every 28 days, or more intensive schedules like 7 days on / 7 days off. Some trials are also exploring different dosages to find the most effective and tolerable regimen.
  • What are researchers hoping to achieve with these temozolomide clinical trials? Researchers are aiming to improve the effectiveness of temozolomide treatment, reduce side effects, and find optimal dosing schedules. They are also exploring its use in different types of brain tumors and in combination with other therapies to potentially enhance overall treatment outcomes for patients with brain cancer.

Ongoing Clinical Trials on Temozolomide

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany

  • Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Poland Spain

  • Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany The Netherlands

  • Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Poland Spain

  • Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +4

  • Study on Preoperative Chemoradiotherapy with Capecitabine and Temozolomide for Patients with Locally Advanced Rectal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Glioblastoma: A fast-growing and aggressive type of brain cancer that forms from glial cells (cells that support nerve cells).
  • Anaplastic glioma: A rare, malignant type of brain tumor that develops from glial cells and is classified as a grade III tumor.
  • Temozolomide: An oral chemotherapy drug used to treat certain types of brain tumors, including glioblastoma.
  • Blood-brain barrier: A protective boundary that separates the brain from the bloodstream, preventing many substances from entering the brain.
  • Chemoradiation: A treatment approach that combines chemotherapy and radiation therapy.
  • MGMT: Methylguanine methyltransferase, an enzyme that can repair DNA damage caused by chemotherapy drugs like temozolomide.
  • IDH mutation: A genetic alteration in the isocitrate dehydrogenase (IDH) gene, which can affect prognosis and treatment response in some brain tumors.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients diagnosed with the disease are still alive.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT03463733
  2. https://clinicaltrials.gov/study/NCT05128734
  3. https://clinicaltrials.gov/study/NCT00740636
  4. https://clinicaltrials.gov/study/NCT00003062
  5. https://clinicaltrials.gov/study/NCT00885534
  6. https://clinicaltrials.gov/study/NCT01534845
  7. https://clinicaltrials.eu/trial/study-of-palbociclib-with-drug-combinations-for-children-and-young-adults-with-recurrent-or-refractory-neuroblastoma-and-ewing-sarcoma/
  8. https://clinicaltrials.gov/study/NCT06258018